Literature DB >> 9853246

Treatment of acute renal failure.

R A Star1.   

Abstract

Acute renal failure is a life threatening illness whose mortality has remained high since the introduction of hemodialysis 25 years ago, despite advances in supportive care. Acute renal failure is an extremely morbid and costly disorder with a significant proportion of patients progressing to end-stage renal disease requiring dialysis. To the nephrologist, acute renal failure remains an extremely frustrating disease, because the pathophysiology is not well understood and the limited therapeutic options force the nephrologist to sit on the sidelines and wait for renal function to return. For example, dialysis remains the only FDA-approved treatment for acute renal failure, but dialysis may also cause renal injury that prolongs renal failure. The purpose of this perspective is to understand the results of the recent, largely negative, clinical trials in view of recent advances in the epidemiology of ARF. This review will also discuss diagnostic tools, strategies for improved design of clinical trials, and other therapeutic interventions that will be needed to properly treat acute renal failure in the 21st century.

Entities:  

Mesh:

Year:  1998        PMID: 9853246     DOI: 10.1046/j.1523-1755.1998.00210.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  183 in total

1.  Transcriptional analysis of infiltrating T cells in kidney ischemia-reperfusion injury reveals a pathophysiological role for CCR5.

Authors:  Gang Jee Ko; Douglas Linfert; Hye Ryoun Jang; Elizabeth Higbee; Tonya Watkins; Chris Cheadle; Manchang Liu; Lorraine Racusen; Dmitry N Grigoryev; Hamid Rabb
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

Review 2.  The role of the ubiquitin-proteasome system in kidney diseases.

Authors:  Hirotaka Fukasawa
Journal:  Clin Exp Nephrol       Date:  2012-06-09       Impact factor: 2.801

Review 3.  Acute kidney injury in hematopoietic cell transplantation.

Authors:  Amy Kogon; Sangeeta Hingorani
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

Review 4.  NGAL-Siderocalin in kidney disease.

Authors:  Neal Paragas; Andong Qiu; Maria Hollmen; Thomas L Nickolas; Prasad Devarajan; Jonathan Barasch
Journal:  Biochim Biophys Acta       Date:  2012-06-19

5.  Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy.

Authors:  Ana Andres-Hernando; Belda Dursun; Christopher Altmann; Nilesh Ahuja; Zhibin He; Rhea Bhargava; Charles E Edelstein; Alkesh Jani; Thomas S Hoke; Christina Klein; Sarah Faubel
Journal:  Nephrol Dial Transplant       Date:  2012-07-09       Impact factor: 5.992

6.  Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy.

Authors:  Fekade Bruck Sime; Michael S Roberts; Morgyn S Warner; Uwe Hahn; Thomas A Robertson; Sue Yeend; Andy Phay; Sheila Lehman; Jeffrey Lipman; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

7.  Arginase-2 mediates renal ischemia-reperfusion injury.

Authors:  Wesley M Raup-Konsavage; Ting Gao; Timothy K Cooper; Sidney M Morris; W Brian Reeves; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-17

8.  Soluble thrombomodulin protects ischemic kidneys.

Authors:  Asif A Sharfuddin; Ruben M Sandoval; David T Berg; Grant E McDougal; Silvia B Campos; Carrie L Phillips; Bryan E Jones; Akanksha Gupta; Brian W Grinnell; Bruce A Molitoris
Journal:  J Am Soc Nephrol       Date:  2009-01-28       Impact factor: 10.121

9.  Protective effects of glycyrrhizin in a gut hypoxia (ischemia)-reoxygenation (reperfusion) model.

Authors:  Rosanna Di Paola; Marta Menegazzi; Emanuela Mazzon; Tiziana Genovese; Concetta Crisafulli; Martina Dal Bosco; Zhenzhen Zou; Hisanori Suzuki; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2008-10-25       Impact factor: 17.440

Review 10.  Biomarkers of acute kidney injury.

Authors:  Charles L Edelstein
Journal:  Adv Chronic Kidney Dis       Date:  2008-07       Impact factor: 3.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.